financetom
Business
financetom
/
Business
/
Nexperia China unit asserts its independence as tensions with the Netherlands run high
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nexperia China unit asserts its independence as tensions with the Netherlands run high
Oct 18, 2025 6:14 AM

BEIJING (Reuters) -Nexperia's China unit has respected Chinese laws and has the right to operate independently, it said on Saturday, a day after the Netherlands said talks had begun to try to ease tensions over export controls.

As Nexperia became entangled in trade frictions between the United States and China, the Dutch government on September 30 took control of the company that makes chips for carmakers and for consumer electronics. It cited worries about the possible transfer of technology to Nexperia's Chinese parent company, Wingtech.

Days later, on October 4, China's commerce ministry blocked Nexperia from exporting chips from China.  

On Saturday, Nexperia's China unit said on its official WeChat account that all of its employees continued to work under the instructions of the China unit. Its employees have the right to reject any "external instructions" not consented to by its Chinese legal representative, it added.  

Salaries and bonuses would continue to be paid out by Nexperia China, and not by Nexperia Netherlands, it also said. 

Wingtech and Nexperia did not immediately respond to requests for comments. 

The tensions have led to worries in the global automotive and electronic industries of possible chip shortages that could disrupt production.  

Nexperia's chips, which are not technically sophisticated, are needed in large volumes. 

The biggest manufacturing site is in Hamburg, Germany, but according to two sources briefed on the matter, more than 70% of Nexperia's chips are shipped back to China to be packaged in Dongguan, a manufacturing hub in China's southern Guangdong province. 

Volkswagen and BMW both said they were working to identify potential supply risks, but that production in Europe had not been impacted yet.

($1 = 7.1264 Chinese yuan renminbi)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Oil Trading at 10-Week Low as IEA Cuts Demand Forecast and Raises  Supply Outlook
Oil Trading at 10-Week Low as IEA Cuts Demand Forecast and Raises Supply Outlook
Aug 13, 2025
09:18 AM EDT, 08/13/2025 (MT Newswires) -- Oil prices fell to a ten-week low early on Wednesday as another major forecasting agency warned global inventories are on the rise amid higher supply while a report showed an unexpected hike in U.S. inventories. West Texas Intermediate crude was last seen down US$0.19 to US$62.98, the lowest since June 2, while October...
ImmunityBio Says CD19 CAR-NK Early Phase Trial Shows Complete Responses in Non-Hodgkin Lymphoma Patients
ImmunityBio Says CD19 CAR-NK Early Phase Trial Shows Complete Responses in Non-Hodgkin Lymphoma Patients
Aug 13, 2025
09:16 AM EDT, 08/13/2025 (MT Newswires) -- ImmunityBio ( IBRX ) said Wednesday that early findings from a phase I trial using its CD19 CAR-NK natural killer cell therapy showed complete responses in the first patients treated so far with late-stage Waldenstrom macroglobulinemia, a type of non-Hodgkins lymphoma. The study is a first-in-human trial assessing the safety and preliminary efficacy...
Nexxen International's Q2 Non-IFRS Net Income, Revenue Rise
Nexxen International's Q2 Non-IFRS Net Income, Revenue Rise
Aug 13, 2025
09:19 AM EDT, 08/13/2025 (MT Newswires) -- Nexxen International ( NEXN ) reported Q2 non-IFRS net income Wednesday of $0.29 per diluted share, up from $0.18 a year earlier. Analysts polled by FactSet expected $0.18. Revenue for the quarter ended June 30 was $90.9 million, up from $88.6 million a year earlier. Analysts surveyed by FactSet expected $87.2 million. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved